← Leaderboards
Alexander Ploss
University Of Pennsylvania
$13,732,497
Attributed
$21,897,241
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,897,241 · 8
By mechanism
R01$20,969,086 · 5
R21$923,155 · 2
R13$5,000 · 1
Top collaborators
- Lishan Su6 shared
- Alexander Andrianov5 shared
- Thomas R Fuerst5 shared
- Roy A Mariuzza5 shared
- Gilad A Ofek5 shared
- Brian G. Pierce5 shared
- Nevil John Singh5 shared
- Robert E Schwartz4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Jemima A. Frimpong$2,877,299
- Rita J Balice-Gordon$8,027,709
- Jaquelin Page Dudley$7,427,251
Others in their field
Top investigators on “Animal Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$464,525,875
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Joseph E Robertson · Oregon Health & Science University$126,125,279
- Peter Gordon Gillespie · Oregon Health And Science University$105,808,119
- David M Anderson · University Of Washington$102,920,737
- Polly Chang · Sri International$84,271,267
Research focus
Animal ModelLiver DiseasesVirusPrimary Carcinoma Of The Liver CellsCirrhosisHepatocyteInfectionCellsLiverImmune ResponsePublic HealthMouse ModelViralPreventChronicIn VitroIn VivoVaccinesPan GenusHepatitis C VirusVirus DiseasesHepatitis CPersonsIntegration Host Factors
Grant awards (36)
Targeting hepatitis B virus cccDNA during HBV/HIV co-infection$2,395,056
R01 · FY2025 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$1,357,012
R01 · FY2025 · AI
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV$531,385
R01 · FY2025 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$1,410,043
R01 · FY2024 · AI
Targeting hepatitis B virus cccDNA during HBV/HIV co-infection$598,764
R01 · FY2024 · AI · contact PI
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV$577,427
R01 · FY2024 · AI · contact PI
Mechanisms of hepatitis B virus cccDNA formation$554,139
R01 · FY2024 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$179,958
R01 · FY2024 · AI
Mechanisms of hepatitis B virus cccDNA formation$30,051
R01 · FY2024 · AI · contact PI
2024 International Meeting on the Molecular Biology of Hepatitis B Viruses (International HBV Meeting)$5,000
R13 · FY2024 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$1,379,680
R01 · FY2023 · AI
Mechanisms of hepatitis B virus cccDNA formation$554,139
R01 · FY2023 · AI · contact PI
Rational design and efficacy testing of vaccines against HCV$1,410,544
R01 · FY2022 · AI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$783,177
R01 · FY2022 · AI
Mechanisms of hepatitis B virus cccDNA formation$554,139
R01 · FY2022 · AI · contact PI
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV$466,302
R01 · FY2022 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$783,177
R01 · FY2021 · AI
Mechanisms of hepatitis B virus cccDNA formation$554,139
R01 · FY2021 · AI · contact PI
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV$474,798
R01 · FY2021 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$764,288
R01 · FY2020 · AI
Mechanisms of hepatitis B virus cccDNA formation$554,139
R01 · FY2020 · AI · contact PI
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV$477,137
R01 · FY2020 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$30,549
R01 · FY2020 · AI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$783,487
R01 · FY2019 · AI
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV$473,320
R01 · FY2019 · AI · contact PI
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infection$797,362
R01 · FY2018 · AI
Genetic Viral and Host Adaptations to Breach Species Barriers of HCV$506,524
R01 · FY2018 · AI · contact PI
Genetic viral and host adaptations to breach species barriers of HCV$402,500
R01 · FY2017 · AI · contact PI
Genetic viral and host adaptations to breach species barriers of HCV$402,500
R01 · FY2016 · AI · contact PI
Impact of species-specific host responses on restriction of hepatotropic viruses$248,625
R21 · FY2016 · AI · contact PI
Genetic viral and host adaptations to breach species barriers of HCV$402,500
R01 · FY2015 · AI · contact PI
Impact of species-specific host responses on restriction of hepatotropic viruses$222,688
R21 · FY2015 · AI · contact PI
Genetic viral and host adaptations to breach species barriers of HCV$402,500
R01 · FY2014 · AI · contact PI
Transmitted/Founder HCV clones as targets for treatment and eradication.$204,546
R21 · FY2014 · AI
Genetic viral and host adaptations to breach species barriers of HCV$378,350
R01 · FY2013 · AI · contact PI
Transmitted/Founder HCV clones as targets for treatment and eradication.$247,296
R21 · FY2013 · AI